You are here

Drug Forecast

A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The First FDA-Approved Treatment for Tardive Dyskinesia
A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections
A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor
A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis
The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection

Pages